title: [Therapy of ascites with tumor necrosis factor in ovarian cancer].
abstract: The biotechnological production of human recombinant tumour necrosis factor (rHuTNF) makes this drug available for clinical application. This endogenous compound exhibits tumouricidal activity and regulatory functions within the immune system. 20 out of 23 (87%) patients with refractory recurrent malignant ascites from ovarian cancer were successfully treated in a phase-I and II-study. The production of ascites was either completely suppressed or reduced to a minimum for at least 4 weeks after maximally three intraperitoneal (i.p.) applications. Two of the three non-responders were mucinous carcinomas. In the phase-I study the evaluation of a maximal tolerable dose was not possible due to the rapid therapeutic success at low doses of TNF. The effective dosage was 0.08-0.14 mg TNF/m2 given i.p. Side effects which occurred 2 to 24 hours after the application of TNF were flue-like symptoms combined with general malaise. The side effects were not dose related. All concomitant signs and symptoms could be minimized by prophylactic or therapeutic application of indometacine, paracetamol or pethidine. This applied especially for the typical early phase cytokine side effects e.g. chills and febrile temperatures. The side effects were not dose related. The i.p. treatment with rHuTNF appears to be a novel practicable and effective method for palliation in patients with recurrent ascites even in multiple pretreated patients.
authors.affiliation: Universitäts-Frauenklinik, Heidelberg.
authors.forename: M
authors.initials: M
authors.lastname: Kaufmann
authors.forename: H
authors.initials: H
authors.lastname: Schmid
authors.forename: U
authors.initials: U
authors.lastname: Raeth
authors.forename: E M
authors.initials: EM
authors.lastname: Grischke
authors.forename: J
authors.initials: J
authors.lastname: Kempeni
authors.forename: E
authors.initials: E
authors.lastname: Schlick
authors.forename: G
authors.initials: G
authors.lastname: Bastert
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003536:Cystadenocarcinoma / Q000401:mortality / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
chemical_list: D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha
vernacular_title: Aszites-Therapie mit Tumornekrosefaktor beim Ovarialkarzinom.